Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
pharmaphorum
SEPTEMBER 16, 2022
The question now is how to tailor dosage even more closely to fit patients’ needs. “[L]ess Almirall has previously found state-of-the-art therapies for immune-related inflammatory diseases such as hidradenitis suppurativa, alopecia areata, psoriasis, and vitiligo.
Let's personalize your content